- Home
- CNOB vs DVAX Comparison
CNOB vs DVAX Comparison
Compare CNOB & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- DVAX
- Stock Information
- Founded
- CNOB 1982
- DVAX 1996
- Country
- CNOB United States
- DVAX United States
- Employees
- CNOB N/A
- DVAX N/A
- Industry
- CNOB Major Banks
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- CNOB Finance
- DVAX Health Care
- Exchange
- CNOB Nasdaq
- DVAX Nasdaq
- Market Cap
- CNOB 1.3B
- DVAX 1.3B
- IPO Year
- CNOB 1996
- DVAX 2004
- Fundamental
- Price
- CNOB $25.09
- DVAX $9.70
- Analyst Decision
- CNOB Buy
- DVAX Buy
- Analyst Count
- CNOB 1
- DVAX 4
- Target Price
- CNOB $31.00
- DVAX $26.50
- AVG Volume (30 Days)
- CNOB 267.9K
- DVAX 1.9M
- Earning Date
- CNOB 10-23-2025
- DVAX 11-06-2025
- Dividend Yield
- CNOB 2.89%
- DVAX N/A
- EPS Growth
- CNOB N/A
- DVAX N/A
- EPS
- CNOB 0.80
- DVAX N/A
- Revenue
- CNOB $241,854,000.00
- DVAX $316,268,000.00
- Revenue This Year
- CNOB $50.62
- DVAX $23.23
- Revenue Next Year
- CNOB $28.54
- DVAX $16.57
- P/E Ratio
- CNOB $31.22
- DVAX N/A
- Revenue Growth
- CNOB N/A
- DVAX 26.66
- 52 Week Low
- CNOB $20.61
- DVAX $9.20
- 52 Week High
- CNOB $29.31
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- CNOB 53.06
- DVAX 41.54
- Support Level
- CNOB $24.83
- DVAX $9.20
- Resistance Level
- CNOB $25.49
- DVAX $9.94
- Average True Range (ATR)
- CNOB 0.53
- DVAX 0.30
- MACD
- CNOB -0.08
- DVAX -0.05
- Stochastic Oscillator
- CNOB 28.35
- DVAX 40.65
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.